HUMAN RECOMBINANT INSULIN MARKET ANALYSIS

Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022
Code : CMI1797
Pages :205
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

High cost of insulin

Global Human Recombinant Insulin Market: Restraint

The major factors that hinder the growth of the global human recombinant insulin market include high cost of insulin, as patients from low and middle countries are unable to afford it. For instance, in September 2020, an article published by the Office of the Assistant Secretary for Planning and Evaluation (ASPE) at the U.S. Department of Health & Services compared insulin, pricing in the U. S. and in other countries showed that in 2018, the average gross manufacturer price for a normal unit of insulin was more than ten times the price in a sample of 32 foreign countries price of insulin in the U.S were US$ 98.70 and US$ 8.81 in the 32 Non-U.S. the Organization for Economic Co-operation and Development (OECD) countries.

Human Recombinant Insulin Market Report Snapshots